Navigation Links
Qforma Appoints New VP, Business Development
Date:8/6/2012

SANTA FE, N.M., Aug. 6, 2012 /PRNewswire/ -- Qforma, the leading provider of healthcare data analytics and predictive modeling technology, today announced the appointment of Douglas Thiede to Vice President, Business Development. Doug comes to Qforma from Gerson Lehrman Group (GLG), where he was instrumental in driving growth in their life sciences business by establishing and expanding relationships with many of the largest pharmaceutical and medical device companies in the U.S.

"Doug joins our growing Qforma team with a 15 year background in sales, marketing, management, business development and product launches," said Al Reicheg, Chief Commercial Officer of Qforma. "He is an innovative and entrepreneurial strategist whose unique diversity of experience will bring significant value to our customers." 

Prior to GLG, Doug spent several years leading teams in the medical device industry at ABS Med and Source Surgical, where he represented over 15 medical device manufacturers and was responsible for growth across multiple product lines. He was also a sales executive with Aventis Pharmaceuticals (now sanofi-aventis), in the respiratory and diabetes divisions. Doug is a regularly featured panelist at healthcare industry conferences.

About Qforma
Qforma is a healthcare data analytics and predictive modeling company, and the leading provider of influence networking technologies identifying the drivers of revenue, market share and better healthcare outcomes.

Qforma is headquartered in Santa Fe, NM with offices in Princeton, NJ.  More information is available at http://www.Qforma.com 

Media Contacts:
Lisa Haley, Qforma
(505) 989-3558
lhaley@qforma.com

Lauren Abel, MCS Healthcare Public Relations
(800) 477-9626, ext. 324 
laurena@mcspr.com 


'/>"/>
SOURCE Qforma
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Qforma Chief Technologist Honored as One of PharmaVOICE Magazines "100 Most Inspiring People in the Life Sciences"
2. ShangPharma Independent Committee Appoints Financial Advisor
3. genae Appoints Core Lab Directors
4. Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
5. Landauer, Inc. Appoints Peter Cempellin To President Of Landauer Radiation Measurement
6. Optimer Pharmaceuticals Appoints Stephen Newman to Its Board of Directors
7. Quanterix Appoints Paul Chapman as President and Chief Executive Officer
8. Conatus Pharmaceuticals Appoints Daniel Ripley As Head Of Corporate Development
9. ShangPharma Independent Committee Appoints Chairman and Legal Counsel
10. C3i Appoints Jonathan Song to Business Development Executive in Asia
11. Organovo Holdings Appoints James T. Glover to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and Company ... of its phase 3 EXPEDITION3 trial at the 9 ... As previously disclosed, solanezumab did not meet the primary ... solanezumab initiated in people with mild dementia due to ... submissions for solanezumab for the treatment of mild dementia ...
(Date:12/8/2016)... CITY , Dec. 8, 2016 ... US patents for improving the accuracy, reproducibility and ... images in long and small bone orthopaedic applications. ... approach to creating personalized orthopaedic restorations based on ... personalized orthopaedic restorations, the company harnesses the world,s ...
(Date:12/8/2016)... Mass. , Dec. 8, 2016  EIP ... it has obtained proof-of-mechanism for neflamapimod (previously code ... completed Phase 2a clinical trials that demonstrated significant ... Study 302 (12-week treatment) and Study 303 (6-week ... Clinical Trials in Alzheimer,s Disease (CTAD) scientific conference ...
Breaking Medicine Technology:
(Date:12/10/2016)... WASHINGTON, D.C. (PRWEB) , ... December 10, 2016 ... ... children’s Christmas wish lists for Santa are all sources of external stimuli that ... season. For some, the added pressure to spread holiday cheer through gifts, food ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... aural rehabilitation—provided by audiologists—to remain a critical part of public access to hearing ... Administration (FDA) announced this week that, starting immediately, it would no ...
(Date:12/9/2016)... ... December 09, 2016 , ... The Justin Veatch Fund ... (NCADD) is recommending the film Whispering Spirits and its discussion guide for ... as an education tool in the war against teen drug abuse. NCADD is ...
(Date:12/9/2016)... ... December 09, 2016 , ... MEDI+SIGN®, a provider of ... a new solution for Emergency Departments (ED) has been added to their portfolio. ... Department examination rooms, and with a simplified pallet of information available to the ...
(Date:12/8/2016)... ... 08, 2016 , ... After enjoying record-breaking attendance at its ... its 33rd Annual Issues & Research Conference, March 2-3, 2017, at the ... conference is “Persistent Challenges and New Opportunities: Using Research to Accelerate the Dialogue." ...
Breaking Medicine News(10 mins):